Category Archives: Professional News

Sylentis announces new data on the treatment of allergic conjunctivitis

The results of SYL116011 have demonstrated that this treatment reduces the symptoms related to the allergy in 50% to 80%. The ARVO meeting has considered the poster presentation to be of scientific interest, contributing therefore to its release. Around 30% of the worldwide population show allergic symptoms and between 40-80% of them have the symptoms […]

Sylentis presented new results for the treatment of age associated macular degeneration

Topical administration of siRNA could be a new therapeutic option for the treatment of degenerative illnesses of the retina that presents processes of neovascularization .   Madrid, 4th of May, 2018. Within the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), that has been held from the 29th […]

Sylentis announces the clinical results of tivanisiran for the treatment of dry eye syndrome

The studies carried out with tivanisiran showed an improvement in the inflammatory ocular parameters, tear quality, and a reduction in ocular pain, that is associated with dry eye syndrome   Madrid, May 3rd, 2018. Sylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the […]

Sylentis presents new results on its ophthalmological compounds at ARVO 2018

The Company presents the preclinical and clinical results from studies of three molecules for the treatment of dry eye syndrome, macular degeneration and eye allergies. The presentation will take place in the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). That will be held from the 29th of […]

Sylentis presents new data on a new eye drop siRNA for the treatment of retinal diseases avoiding intraocular injections

This new investigational treatment, based on RNA interference, reaches the retina when administered in eye drops. This feature is expected to positively affect patients’ quality of life by eluding the use of current standard treatments administered by intraocular injections.   Madrid, 25 September 2017. Sylentis presents, for the first time, positive data on the efficacy […]

Sylentis initiates a Phase III study for the treatment of dry eye syndrome

HELIX is a Phase III clinical trial started by Sylentis with the investigational new drug SYL1001, based on RNA interference technology (RNAi). The Company has agreed with the U.S. Food and Drug Administration (FDA) on plans for the Phase III clinical program, which is designed to support the submission of a New Drug Application (NDA). […]

Sylentis announces new preclinical and clinical data for its SYL1001 molecule during ARVO 2017

SYL1001 is a compound under investigation for the treatment of dry eye disease. It is a product based on the novel technology RNA interference (RNAi), developed for the treatment of signs and symptoms of this illness. At the Annual Congress of the Association for Research in Vision and Ophthalmology 2017, around 11,000 attendees will meet […]

Sylentis reports positive Phase II results with SYL1001 in treating ocular pain related to dry eye syndrome

Sylentis reports positive Phase II results with SYL1001 in treating ocular pain related to dry eye syndrome Phase II dose-finding and efficacy trials (SYL1001_II and SYL1001_III) achieved their primary endpoints in terms of ocular pain (VAS) (p<0.016) and hyperaemia reduction with a dose of 1.125% (p<0.0134). SYL1001 was well tolerated at all evaluated doses and […]

Sylentis announces top-line results from Phase II study SYLTAG for RNAi drug bamosiran (SYL040012) in Glaucoma

All bamosiran doses similarly reduced the intraocular pressure (IOP). In patients with a baseline IOP greater than or equal to 25 mm Hg, 1.125% bamosiran showed more efficacy  The trial did not meet the secondary objective of demonstrating non-inferiority compared to timolol in the total patient population; however, bamosiran at dose 1.125% ((450 micrograms) showed […]

Sylentis receives authorisation to commence Phase IIb clinical trial with bamosiran (SYL040012) for treating ocular hypertension associated with glaucoma

The main endpoint of the trial is to establish the most effective dose of bamosiran for reducing intraocular pressure after 28 days’ treatment.  The Phase IIb trial with bamosiran will be conducted at 21 centres in Spain, Germany, Estonia and the United States, enrolling 180 patients. Madrid, 17 July 2014: Grupo Zeltia (MC:ZEL) has announced today […]

error: Content is protected !!